TrialCard, with a 17-year history of providing strategic guidance and integrated services to help customers deliver optimal patient outcomes, is one of the preeminent patient services organizations in the United States. Headquartered in Morrisville, North Carolina, the Company provides outsourced tech-enabled sales and marketing services to pharmaceutical, biotech, diagnostics, and medical device clients that help drive an improved patient experience and access for prescription medications. TrialCard operates under three business segments: Patient Affordability (co-pay savings and voucher programs), Market Access (TrialCard's hub services division), and Virtual Engagement (outbound tele-promotion and healthcare professional lead generation solutions).

Jeff McKibben, a Managing Principal of Odyssey, said: “TrialCard is a well-positioned business in a dynamic industry, led by a deep and experienced leadership team. Our investment represents a compelling opportunity to execute a multi-faceted growth strategy in an attractive market. We look forward to partnering with Mark Bouck and his team to continue building a highly valuable provider of outsourced services to pharmaceutical companies.”

The TrialCard management team, including CEO Mark Bouck, will continue to lead the organization under Odyssey's ownership.

Mr. Bouck said: “We are excited to begin our new partnership with Odyssey. During the last several months, it was evident that this new relationship will provide us with an experienced partner with the expertise and capital to support our strategy and continue developing solutions for complex patient access challenges. We look forward to continuing our mission to provide innovative solutions to pharmaceutical manufacturers, providers, pharmacies and patients.”

Brad Cornell, a Partner of Excellere Partners, added: “We are grateful for the opportunity to support Mark and his team in pursuit of their vision to build a leading medication adherence solutions provider. Our partnership enabled us to leverage Excellere’s value creation methodology to augment TrialCard’s service offering with complementary capabilities, enhance its systems and processes, and establish a scalable foundation that will position the Company to capitalize on the multitude of growth avenues in the industry. We continue to see strong tailwinds in the outsourced pharma services market, and are enthusiastic about the Company’s future with Odyssey.”

Contacts

For Odyssey Investment Partners: Mark Semer
Kekst
(212) 521-4800